A practical reference on GLP-1 receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-12 and is reviewed periodically as new material appears.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
| Property | Value | Notes |
|---|---|---|
| Molar mass | approximately 4813 Da | calculated from the 39-residue sequence |
| Appearance | white to off-white powder | typical of lyophilised peptide material |
| Solubility class | freely soluble in water | measured value depends on salt form and pH |
| Plasma protein binding | >99 percent | linked to the fatty diacid side chain |
| Class | dual GIP and GLP-1 receptor agonist | receptor activity varies with the assay used |
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Molecular medicine (the broader field of the molecular understanding of disease) Molecular pathology Laboratory Developed Test Pathogenesis Pathogenomics Pathology Precision medicine Personalized medicine
== Physical properties and characterization == Esters derived from carboxylic acids and alcohols are more polar than ethers but less polar than alcohols. They participate in hydrogen bonds as hydrogen-bond acceptors, but cannot act as hydrogen-bond donors, unlike their parent alcohols. This ability to participate in hydrogen bonding confers some water-solubility. Because of their lack of hydrogen-bond-donating ability, esters do not self-associate. Consequently, esters are more volatile than carboxylic acids of similar molecular weight.
Many of these conditions, if severe enough, can damage the heart so much that the pumping function of the heart is reduced. If the heart is no longer able to pump enough blood to meet the body's needs, this is described as heart failure. Significant damage to cardiac muscle cells is referred to as myocytolysis which is considered a type of cellular necrosis defined as either coagulative or colliquative.
Keloid, also known as keloid disorder and keloidal scar, is the formation of a type of scar which, depending on its maturity, is composed mainly of either type III (early) or type I (late) collagen. It is a result of an overgrowth of granulation tissue (collagen type III) at the site of a healed skin injury, which is then slowly replaced by collagen type I. Keloids are firm, rubbery lesions or shiny, fibrous nodules, and can vary from pink to the color of the person's skin or red to dark brown. A keloid scar is benign and not contagious, but sometimes accompanied by severe itchiness, pain, and changes in texture. In severe cases, it can affect the movement of the skin. In the United States, keloid scars are seen 15 times more frequently in people of sub-Saharan African descent than in people of European descent. There is a higher tendency to develop a keloid among those with a family history of keloids and people between the ages of 10 and 30 years. Keloids should not be confused with hypertrophic scars, which are raised scars that do not grow beyond the boundaries of the original wound.
About 19 radioisotopes and 7 nuclear isomers, 233Cm to 251Cm, are known; none are stable. The longest half-lives are 15.6 million years (247Cm) and 348,000 years (248Cm). Other long-lived ones are 250Cm (~8300 years), 245Cm (8250 years), and 246Cm (4706 years). Curium-250 is unusual: it mainly decays by spontaneous fission (only mode observed). The most common isotopes are 242Cm and 244Cm with the half-lives 162.8 days and 18.11 years, respectively.
Sources: en.wikipedia.org
=== Lawsuits === In September 2009, the U.S. Justice Department announced that Pfizer had been ordered to pay a historic fine of $2.3 billion as a penalty for fraudulent marketing of several drugs, including Geodon. Matthew Dougherty, a 51‑year‑old former teacher and artist with a diagnosis of schizophrenia, died on May 21, 2024, at Phoenixville Hospital in Phoenixville, Pennsylvania. According to a wrongful death lawsuit filed by his family in March 2025, Dougherty had been admitted to the hospital after a mental health crisis during which he was tased by police and suffered injuries. While hospitalized, Dougherty's regular psychiatric medications were discontinued. On the evening of his death, an alarm sounded in a nearby room, causing him to become agitated. Hospital staff called the police to restrain him, and responding officers again used a taser on Dougherty. Shortly afterward, nurses administered two doses of Geodon (ziprasidone) – a total of 40 mg, an amount the lawsuit equated to "administering poison". Minutes later, Dougherty went into cardiac arrest and could not be resuscitated. The lawsuit names as defendants Tower Health, which operates Phoenixville Hospital, and seeks damages for wrongful death and negligence. At the time the suit was filed, Tower Health had not filed a response to the complaint.
Liu had seized the Chengdu Arsenal in 1925 after Yang Sen's downfall, but to appease the city's other warlords, he announced plans to convert it into a mechanical repair shop rather than a weapons factory. To oversee this process, he appointed his brother Liu Wencheng, who had previously run a distillery, as its manager. Liu Wencheng would also later be appointed to several managerial positions in industrial enterprises. The Chengdu Arsenal would eventually be converted into a mint, increasing Liu Wenhui's money supply. Liu's brother Wencheng used his position in Chengdu to purchase houses and land, expanding his family's real estate holdings. He purchased so much property that his rivals nicknamed him "Liu Half-City", implying he owned half of Chengdu. Liu Wenhui's army continued growing due to money and industrial supplies from his brothers. Over the course of 1926, he attacked and disarmed the forces of Yang Chunfang in January and Lü Chao in April, taking control of Lü's territories in southern Sichuan. To formalize the division of Chengdu, Liu, Deng, and Tian established a joint command in December 1926 with Liu as director. In December 1926, communist forces under Liu Bocheng launched the Luzhou Uprising in Sichuan as part of the Northern Expedition. Liu Bocheng's forces successfully took control of the city from warlord Lai Xinhui. Control of Luzhou was coveted by several neighboring warlords, who had also begun besieging the city. To prevent his rivals from capturing Luzhou, Liu dispatched his friend Leng Yingdong to surround the city in April 1927.
The research assistant's job can include some or all of the following: providing the local institutional review board (IRB) with the documentation necessary to obtain its permission to conduct the study, assisting with study start-up, identifying eligible patients, obtaining consent from them or their families, administering study treatment(s), collecting and statistically analyzing data, maintaining and updating data files during followup, and communicating with the IRB, as well as the sponsor and CRO.
Nicomorphine (Vilan, Subellan, Gevilan, MorZet) is the 3,6-dinicotinate ester of morphine. It is a strong opioid agonist analgesic two to three times as potent as morphine with a side effect profile similar to that of dihydromorphine, morphine, and diamorphine. Nicomorphine was first synthesized in 1904 and was patented as Vilan by Lannacher Heilmittel G.m.b.H. of Austria in 1957.
== External links == Official website Historic American Engineering Record (HAER) No. AL-188, "Atlantic Ice and Coal Company, 135 Prince Street, Montgomery, Montgomery County, AL", 23 photos, 14 measured drawings, 37 data pages, 2 photo caption pages Business data for Americold Realty Trust, Inc.:
Sources: en.wikipedia.org
== Portrayals in news == Inaccurate portrayals of mental health in the news ultimately affect the audience's thoughts, attitudes, opinions, and beliefs, not only for the mentally ill but also for the illnesses themselves, the treatment required, and the public policy necessary to implement initiatives for change. However, these dramatic stories may not be the only culprit for swaying public opinion. Consistent patterns of misinformation, framing, and one-sided perspectives have the same ability to shape public perception. In 1991, a content analysis of United Press International stories found that stories about psychiatric patients usually involved violent crimes. In a similar study by Wahl, Wood, and Richards, they analyzed the common themes present in 1999 stories about mental illness amongst six major newspapers: The New York Times, The Washington Post, St. Louis Post-Dispatch, The Boston Globe, Los Angeles Times, and the St. Petersburg Times (Tampa Bay Times). Of the 300 randomly selected stories containing the phrase "mental illness," dangerousness was the overwhelming theme across all six publications, with 26% involving violence or criminal activity by a mentally ill person. The consistent pattern of linking mental illness and violence not only leads to the public being fearful or avoidant of mentally ill people but also less likely to offer or support community care.
== Awards == In 2004 the ELGA CENTRA received an Industrial Product Design Award; in 2009 the PURELAB Ultra was the Readers Choice Laboratory Equipment winner: the ELGA PURELAB flex received the Instrument Business Outlook (IBO) Silver design award for Laboratory Equipment Industrial Design in 2009, the Aquatech China Innovation Gold Award in 2010 and the Industrial Product Design Gold Award, the Materials Innovation Gold Award, the dBA Design Effectiveness and the Red Dot Award in 2011; in 2011 the ELGA PURELAB Pulse also received the Scientists Choice Award.
Metabolism involves a vast array of chemical reactions, but most fall under a few basic types of reactions that involve the transfer of functional groups of atoms and their bonds within molecules. This common chemistry allows cells to use a small set of metabolic intermediates to carry chemical groups between different reactions. These group-transfer intermediates are called coenzymes. Each class of group-transfer reactions is carried out by a particular coenzyme, which is the substrate for a set of enzymes that produce it, and a set of enzymes that consume it. These coenzymes are therefore continuously made, consumed and then recycled. One central coenzyme is adenosine triphosphate (ATP) which is the energy currency of cells. This nucleotide is used to transfer chemical energy between different chemical reactions. There is only a small amount of ATP in cells, but as it is continuously regenerated, the human body can use about its own weight in ATP per day. ATP acts as a bridge between catabolism and anabolism. Catabolism breaks down molecules, and anabolism puts them together. Catabolic reactions generate ATP, and anabolic reactions consume it. It also serves as a carrier of phosphate groups in phosphorylation reactions. A vitamin is an organic compound needed in small quantities that cannot be made in cells. In human nutrition, most vitamins function as coenzymes after modification; for example, all water-soluble vitamins are phosphorylated or are coupled to nucleotides when they are used in cells.
=== Augmentation of Tumor Necrosis Factor === Injection of tuftsin intraperitoneally increases the formulation of TNF in serum and supernatants of cultured splenic and peritoneal adherent cells. This was also demonstrated in vitro using HL60 leukemia cells.
Sources: en.wikipedia.org
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.
The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.
In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.